FINWIRES · TerminalLIVE
FINWIRES

HKG:6872

4 stories mentioning HKG:6872Updated 45d ago

Every FINWIRES story that references HKG:6872, newest first.

Asia

Hong Kong Stocks End Higher After Roller Coaster Week; TenNor Therapeutics Soars in Debut

Hong Kong stocks zigzagged between gains and losses over the past four sessions, but managed to end the tumultuous week in positive territory.The Hang Seng Index rose by 219.51 points, or 0.9%, to end at 25,606.03, while the Hang Seng China Enterprises Index increased by 75.55 points, or 0.9%, to close at 8,550.87.U.S. Secretary of State Marco Rubio said there had been "some good signs" in talks between Washington and Tehran, but both sides remained at odds over Iran's uranium stockpile and controls on the Strait of Hormuz, Reuters reported.Meanwhile, analysts warned that the upcoming global initial public offering of Elon Musk's SpaceX could siphon off funds from the broader Asia-Pacific region, including Hong Kong, in preparation for subscriptions, the South China Morning Post reported.The aerospace company is reportedly seeking $75 billion in what could be the world's largest IPO, topping Saudi Aramco's $29.4 billion offering in 2019.In local development, Hong Kong's consumer inflation held steady at 1.7% year over year in April, unchanged from the previous month.Hong Kong financial markets will be closed on Monday, May 25, for a local holiday and reopen on Tuesday, May 26.In corporate news, Chinese biotech firm TenNor Therapeutics (HKG:6872) had a stellar debut in Hong Kong as its shares closed at HK$211, 179% higher than its IPO price of HK$75.70.

Hang SengHKG:6872
Asia

TenNor Therapeutics Soars 98% in Hong Kong Trading Debut

TenNor Therapeutics' (HKG:6872) shares opened 98% above their initial public offering price in a stellar Hong Kong debut on Friday morning.The China-based near-commercial stage biotechnology company opened at HK$150 per share, well above the offer price of HK$75.70.

HKG:6872
Asia

TenNor Therapeutics Nets HK$598 Million From Hong Kong IPO Ahead of Debut

TenNor Therapeutics (Suzhou) (HKG:6872) raised HK$598.3 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$75.70 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.The China-based near-commercial stage biotechnology company offered 8.9 million H-shares in the global offering.The Hong Kong public offer was 9,015.11 times subscribed, with a final allocation of 828,100 shares, representing 9.35% of the total offering.The international offering was 9.24 times subscribed, with a final allocation of 8 million shares, or 90.65% of the total offering.An additional 575,450 shares were issued under the partial exercise of the offer size adjustment option.Cornerstone investors, including AMR Action Fund, Hua Yuan International, and Orient Asset Management, were allotted a combined 3.1 million shares, representing 34.81% of the global offering, according to the filing.TenNor Therapeutics is set to debut on the Hong Kong bourse on Friday, May 22.

HKG:6872
Asia

TenNor Therapeutics Launches Up to HK$627 Million Hong Kong IPO

TenNor Therapeutics (HKG:6872) launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$626.8 million from the deal.The China-based near-commercial stage biotechnology company is offering 8.3 million shares at HK$75.70 each, according to a Hong Kong bourse filing.The offering comprises 828,100 shares for Hong Kong investors and 7.5 million shares for international investors, subject to reallocation, the offer size adjustment option, and the overallotment option.Allocation results are due by May 21, ahead of the company's planned trading debut on May 22.Net proceeds will be used mainly to fund the research, development, regulatory filings, and commercialization of core products rifasutenizol and rifaquizinone injection.The funds will also be used to support clinical development of TNP-2092, advance other pipeline candidates, construct an in-house manufacturing facility in Guangdong, and for working capital and general corporate purposes.CITIC Securities (Hong Kong) and ABCI Capital are acting as joint sponsors.CLSA and ABCI Capital are serving as sponsor-overall coordinators, overall coordinators, and joint global coordinators, while also acting as joint bookrunners alongside China Renaissance Securities (Hong Kong).CLSA, ABCI Securities Company, China Renaissance Securities (Hong Kong), Futu Securities International (Hong Kong), and Tiger Brokers (HK) Global are acting as joint lead managers.

HKG:6872

Track with the FINWIRES app suite